Ocrelizumab is an anti-CD20 monoclonal antibody used in the treatment of relapsing remitting and primary progressive multiple sclerosis. The main side effects are infusion-related with long term administration raising the risk of infections. During randomized controlled trials five cases of pancreatitis have been reported. We present a case of a patient with no risk factors for pancreatitis who after administration developed acute pancreatitis albeit with a good recovery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2020.102381 | DOI Listing |
Publication Analysis
Top Keywords
acute pancreatitis
8
treatment relapsing
8
relapsing remitting
8
multiple sclerosis
8
pancreatitis ocrelizumab
4
ocrelizumab treatment
4
remitting multiple
4
sclerosis ocrelizumab
4
ocrelizumab anti-cd20
4
anti-cd20 monoclonal
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!